ETM
COLL icon

Euclidean Technologies Management’s Collegium Pharmaceutical COLL Stock Holding History

Euclidean Technologies Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,900
Closed -$193K – 70
2022
Q2 		$193K Hold
10,900
– – 0.2% 65
2022
Q1 		$222K Hold
10,900
– – 0.21% 69
2021
Q4 		$204K Buy
+10,900
New +$212K 0.17% 86

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Euclidean Technologies Management's COLL Position: Q3 2022 in Review

Euclidean Technologies Management sold out of Collegium Pharmaceutical (COLL) in Q3 2022, closing a stake of 10,900 shares — an estimated $193K sold.

Euclidean Technologies Management first reported a position in COLL in Q4 2021 and held it in 3 quarters. The position peaked at $222K in Q1 2022. 168 funds tracked by Wall St. Rank hold COLL as of Q3 2022.

  • Euclidean Technologies Management reported no remaining Collegium Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Euclidean Technologies Management sold 10,900 Collegium Pharmaceutical shares in Q3 2022, an estimated $193K.
  • Euclidean Technologies Management first reported a position in Collegium Pharmaceutical in Q4 2021 and held it in 3 quarters.
  • Euclidean Technologies Management's Collegium Pharmaceutical position peaked at $222K in Q1 2022.
  • 168 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2022.

Based on Euclidean Technologies Management's 13F filing for Q3 2022, filed 28 Oct 2022.